HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Exner, D. V. Articles by Domanski, M. J. Search for Related Content PubMed PubMed Citation Articles by Exner, D. V. Articles by Domanski, M. J.

Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction

Derek V. Exner, MD^1,*, Daniel L. Dries, MD, MPH^*, Myron A. Waclawiw, PhD, Brent Shelton, PhD and Michael J. Domanski, MD, FACC^*

^* Clinical Trials Scientific Research Group, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
Office of Biostatistics Research, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
Section on Biostatistics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

View larger version (17K): [in a new window]   Figure 1 Unadjusted all-cause mortality survival curves for Prevention trial participants. Patients receiving neither enalapril nor a beta-blocker (neither) are represented by the broken gray line, those receiving enalapril alone by the solid gray line, patients receiving beta-blockers alone by the broken black line and those receiving both enalapril and a beta-blocker (both) by the solid black line. The number of patients at risk of death during each 365-day period is shown. Patients with asymptomatic left ventricular dysfunction who received both a beta-blocker and enalapril had the lowest mortality (p 0.03).

View larger version (18K): [in a new window]   Figure 2 Unadjusted all-cause mortality survival curves for Treatment trial participants. Patients receiving neither enalapril nor a beta-blocker (neither) are represented by the broken gray line, those receiving enalapril alone by the solid gray line, patients receiving beta-blockers alone by the broken black line and those receiving both enalapril and a beta-blocker (both) by the solid black line. The number of patients at risk of death during each 365-day period is shown.